Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study

H Lee Moffitt Cancer Center, Tampa, FL, USA. anna.giuliano@moffi
The Lancet (Impact Factor: 45.22). 02/2011; 377(9769):932-40. DOI: 10.1016/S0140-6736(10)62342-2
Source: PubMed

ABSTRACT Human papillomaviruses (HPVs) cause genital warts and cancers in men. The natural history of HPV infection in men is largely unknown, and that information is needed to inform prevention strategies. The goal in this study was to estimate incidence and clearance of type-specific genital HPV infection in men, and to assess the associated factors.
Men (aged 18-70 years), residing in Brazil, Mexico, and the USA, who were HIV negative and reported no history of cancer were recruited from the general population, universities, and organised health-care systems. They were assessed every 6 months for a median follow-up of 27·5 months (18·0-31·2). Specimens from the coronal sulcus, glans penis, shaft, and scrotum were obtained for the assessment of the status of HPV genotypes.
In 1159 men, the incidence of a new genital HPV infection was 38·4 per 1000 person months (95% CI 34·3-43·0). Oncogenic HPV infection was significantly associated with having a high number of lifetime female sexual partners (hazard ratio 2·40, 1·38-4·18, for at least 50 partners vs not more than one partner), and number of male anal-sexual partners (2·57, 1·46-4·49, for at least three male partners vs no recent partners). Median duration of HPV infection was 7·52 months (6·80-8·61) for any HPV and 12·19 months (7·16-18·17) for HPV 16. Clearance of oncogenic HPV infection decreased in men with a high number of lifetime female partners (0·49, 0·31-0·76, for at least 50 female partners vs not more than one partner), and in men in Brazil (0·71, 0·56-0·91) and Mexico (0·73, 0·57-0·94) compared with the USA. Clearance of oncogenic HPV was more rapid with increasing age (1·02, 1·01-1·03).
The data from this study are useful for the development of realistic cost-effectiveness models for male HPV vaccination internationally.
National Cancer Institute.

Download full-text


Available from: Anna R Giuliano, Jul 08, 2015
1 Follower
  • Source
    • "A high prevalence of HPV (44.8%) is found in U.S. women 20 to 24 years old (30% low and 28% high-risk subtypes), compared with 24.5% for U.S. women over the broader age range of 14 to 49 (Dunne et al., 2007). Risk might be even greater for men: 50% prevalence was reported among men 18 to 70 years old (38% low risk and 30% high risk subtypes; Giuliano et al., 2011). There is no treatment for the virus, and although most precancerous cells normalize on their own, some do not and can cause anogenital warts and cervical, vulvar, vaginal, penile, anal, or oropharangeal cancer (CDC, 2013b), as well as psychological and sexual consequences (e.g., anger, anxiety, stigma, lower sexual desire) for the individual and relationship partner(s) (Chaturvedi, 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The odds of developing cancer are increased by specific lifestyle behaviors (tobacco use, excess energy and alcohol intakes, low fruit and vegetable intake, physical inactivity, risky sexual behaviors, and inadequate sun protection) that are established risk factors for developing cancer. These behaviors are largely absent in childhood, emerge and tend to cluster over the life span, and show an increased prevalence among those disadvantaged by low education, low income, or minority status. Even though these risk behaviors are modifiable, few are diminishing in the population over time. We review the prevalence and population distribution of these behaviors and apply an ecological model to describe effective or promising healthy lifestyle interventions targeted to the individual, the sociocultural context, or environmental and policy influences. We suggest that implementing multiple health behavior change interventions across these levels could substantially reduce the prevalence of cancer and the burden it places on the public and the health care system. We note important still-unresolved questions about which behaviors can be intervened upon simultaneously in order to maximize positive behavioral synergies, minimize negative ones, and effectively engage underserved populations. We conclude that interprofessional collaboration is needed to appropriately determine and convey the value of primary prevention of cancer and other chronic diseases. (PsycINFO Database Record (c) 2015 APA, all rights reserved).
    American Psychologist 02/2015; 70(2):75-90. DOI:10.1037/a0038806 · 6.87 Impact Factor
  • Source
    • "Visual inspection of the external genital skin was conducted and exfoliated cells were collected from the normal genital skin. Using Dacron swabs prewetted with sterile saline, the penile head, penile shaft, and scrotum were sampled, combined into one specimen, and archived [19]. If an EGL was identified, exfoliated cells from the surface of the lesion were "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cutaneous human papillomaviruses (HPVs) may be associated with cutaneous epithelial lesions and non-melanoma skin cancers. No study has systematically evaluated the presence of genus beta [β]-HPV in male genital skin or external genital lesions (EGLs) OBJECTIVES: To examine cutaneous β-HPV types detected on the surface of EGLs in men and describe their presence prior to EGL development. A retrospective case series was conducted among 69 men with pathologically confirmed EGLs (n=72) who participated in the HPV Infection in Men Study. Archived exfoliated cells collected from the surface of each EGL and normal genital skin specimens 6-12 months preceding EGL development were tested for β-HPV DNA using a type-specific multiplex genotyping assay. β-HPV DNA was detected on 61.1% of all EGLs, with types 38 (16.7%), 5 (15.3%), and 12 (12.5%) most commonly identified. HPV prevalence differed across pathological diagnoses, with the largest number of β-HPV types detected on condylomas. Most β-HPV types were detected on normal genital skin prior to EGL development, though the prevalence was lower on EGLs compared to preceding normal genital skin. EGLs and the normal genital skin of men harbor a large number of β-HPV types; however, it appears that β-HPVs are unrelated to EGL development in men. Despite evidence to support a causal role in skin carcinogenesis at UVR-exposed sites, cutaneous HPV appears unlikely to cause disease at the UVR-unexposed genitals.
    Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 10/2013; 58(4). DOI:10.1016/j.jcv.2013.10.011 · 3.47 Impact Factor
  • Source
    • "Genital infection with the human papillomavirus (HPV) is common in men; the lifetime risk of acquiring an anogenital HPV infection exceeds 50% [1] [2]. Over 40 HPV types (the alpha genus) are capable of infecting the genital epithelium, though not all of these types are oncogenic. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A small number of HPV types are related to a majority of HPV-related neoplastic lesions in humans. High-risk types such as HPV 16 and 18 are most often implicated, although other oncogenic and non-oncogenic HPV types can cause disease in men. The efficacy of the quadrivalent HPV vaccine (qHPV) against external genital lesions and intra-anal disease related to HPV in men has been demonstrated. This report examines the vaccine's efficacy against disease due to 10 additional non-vaccine HPV types, as well as efficacy regardless of HPV detection. The data presented suggest that vaccinating males against HPV 6, 11, 16 and 18 protects them against most vaccine HPV-type related anogenital disease. However, significant efficacy against disease due to non-vaccine HPV types was not seen. In addition, the data do not provide any evidence that vaccination with qHPV vaccine will increase the likelihood of disease caused by non-vaccine types in the short term.
    Vaccine 07/2013; 31(37). DOI:10.1016/j.vaccine.2013.06.057 · 3.49 Impact Factor